{"id":765352,"date":"2023-06-22T07:34:02","date_gmt":"2023-06-22T11:34:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/"},"modified":"2023-06-22T07:34:02","modified_gmt":"2023-06-22T11:34:02","slug":"opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/","title":{"rendered":"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been received<\/em>\n        <\/li>\n<li>\n          <em>Latest C-Series Unyvero A30 instruments optimized for series production and clinical trials<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">ROCKVILLE, Md., June  22, 2023  (GLOBE NEWSWIRE) &#8212; OpGen, Inc. (Nasdaq: OPGN, \u201cOpGen\u201d or \u201cthe Company\u201d), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.<\/p>\n<p align=\"justify\">These C-Series instruments incorporate all learnings from extensive testing of the 10 B-Series instruments over the past 12 months. The C-Series instruments have been optimized and improved for manufacturability, serviceability and robustness. They have also been optimized for extended lifetime of all key moving parts inside the instruments, as well as cost of goods in the manufacturing process of these A30 instruments.<\/p>\n<p align=\"justify\">Andreas Boos, CTO of Curetis and program lead of the Unyvero A30 platform project commented: \u201cWe are excited to have taken possession of this newest batch of instruments. With all of the improvements made to date, this is now very close to the final release version of the product. We intend to use the A30 C-Series instruments in all further product development and clinical trials as well as regulatory submissions for our application cartridges on the A30 system.\u201d Mr. Boos added that, \u201call of our ten B-Series instruments have also been upgraded to this latest standard to plan for sufficient A30 instruments to be available for the continued development of our own assays and cartridges in house, and for collaborative projects such as the FIND R&amp;D collaboration which aims to bring an A30 platform and antimicrobial resistance (AMR) test from blood cultures to low and middle income countries, as well as for other R&amp;D collaboration projects funded by third party partners.\u201d<\/p>\n<p>\n        <strong>About OpGen, Inc. <\/strong>\n      <\/p>\n<p align=\"justify\">OpGen, Inc.\u00a0(Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries,\u00a0Curetis GmbH\u00a0and\u00a0Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen\u2019s current product portfolio includes Unyvero,\u00a0Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TPPgcH5C1zivaZ8ySzffNfBA7FLkMeR7isYyFhRDvX419o8yhFPc-LDwoetednwvLEDQ_aGEv4BDZpFf_jsOb-QGjKh3GjLLhX7dowfzgRT3Y_8s06LCL0iQoLyNkbR7EhtwEJSwHwRorrQpJVh7AaCe-Q_z2BiQJ2-7JCvrGcUXbK7hSxSr0oQJ4AbmN5Vi_BMB4cBt88LYiJkTZ3o9KJTGTFQhzjbvk3JRJUFRFsc=\" rel=\"nofollow noopener\" target=\"_blank\">www.opgen.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes statements regarding OpGen\u2019s C-Series Unyvero A30 instruments.\u00a0\u00a0 These statements and other statements regarding OpGen\u2019s future plans and goals constitute &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen&#8217;s business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>OpGen:<\/strong><br \/>\n        <br \/>Oliver Schacht<br \/>President and CEO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vEt64hSpLIEGW-NI1nJn7mYCtBLD9OqjXe9K9tI8KCuyNK8FpOrWyvykpVD-PgXzKC70aTCNc0nGX-IVLEyy8JS-z0ruy7UUoG6VIQvwi1EMOm-NSBEDZOYmMaGhXAIU\" rel=\"nofollow noopener\" target=\"_blank\">InvestorRelations@opgen.com<\/a><\/p>\n<p>\n        <strong>OpGen Investor &amp; Press Contact:<\/strong><br \/>\n        <br \/>Alyssa Factor<br \/><strong>Edison Group<\/strong><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m1038GoZKFtp1IBPBKOMLJqyRlnH8q3a3nCTRkiaglhrgMrAU_j1QiNYsa1GvqdNLx1jnz7AuRYAvl9i4hiN59JtJw-uiLZ6tBw8OB_fSk8=\" rel=\"nofollow noopener\" target=\"_blank\">afactor@edisongroup.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2Y2Y2IyNmMtMTI4NS00MDkwLWFlZmYtNGIyNTA5OWVhOWUxLTEwMjkxOTk=\/tiny\/OpGen-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been received Latest C-Series Unyvero A30 instruments optimized for series production and clinical trials ROCKVILLE, Md., June 22, 2023 (GLOBE NEWSWIRE) &#8212; OpGen, Inc. (Nasdaq: OPGN, \u201cOpGen\u201d or \u201cthe Company\u201d), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats. These C-Series instruments incorporate all learnings from &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765352","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been received Latest C-Series Unyvero A30 instruments optimized for series production and clinical trials ROCKVILLE, Md., June 22, 2023 (GLOBE NEWSWIRE) &#8212; OpGen, Inc. (Nasdaq: OPGN, \u201cOpGen\u201d or \u201cthe Company\u201d), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats. These C-Series instruments incorporate all learnings from &hellip; Continue reading &quot;OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-22T11:34:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments\",\"datePublished\":\"2023-06-22T11:34:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/\"},\"wordCount\":804,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/\",\"name\":\"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=\",\"datePublished\":\"2023-06-22T11:34:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/","og_locale":"en_US","og_type":"article","og_title":"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments - Market Newsdesk","og_description":"Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been received Latest C-Series Unyvero A30 instruments optimized for series production and clinical trials ROCKVILLE, Md., June 22, 2023 (GLOBE NEWSWIRE) &#8212; OpGen, Inc. (Nasdaq: OPGN, \u201cOpGen\u201d or \u201cthe Company\u201d), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats. These C-Series instruments incorporate all learnings from &hellip; Continue reading \"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-22T11:34:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments","datePublished":"2023-06-22T11:34:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/"},"wordCount":804,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/","name":"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=","datePublished":"2023-06-22T11:34:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1OTMxOSM1NjUwNDE2IzIwMTc2MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OpGen\u2019s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765352"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765352\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}